Core Insights - The company announced the latest research results of two globally innovative drugs at the 67th American Society of Hematology (ASH) conference, highlighting advancements in T-cell lymphoma and B-cell lymphoma treatments [1] Group 1: Drug Development - The high-selective JAK1 inhibitor, Golixtin (generic name: Golixtin capsules), has made significant progress in the field of T-cell lymphoma [1] - The non-covalent LYN/BTK dual-target inhibitor, birelentinib (DZD8586), has shown promising clinical data in the treatment of B-cell lymphoma [1] Group 2: Clinical Trial Results - In the Phase III recommended dose (RP3D) of 50mg, the overall response rate (ORR) was 84.2% [1] - Tumor remission was observed in patients who had previously received BTK inhibitors, Bcl-2 inhibitors, or BTK degraders, including those with classic BTK resistance mutations (C481X) or other BTK mutations [1] - The anti-tumor efficacy was durable, and safety was good, with no new safety issues reported during the follow-up period [1]

Core Viewpoint - The company DiZhe Pharmaceutical (688192) announced significant advancements in two innovative drugs at the 67th American Society of Hematology (ASH) conference, focusing on treatments for T-cell and B-cell lymphomas [1] Group 1: Drug Developments - The high-selectivity JAK1 inhibitor, Goli Siti Ni (generic name: Golisitini capsules), has made multiple new progressions in the field of T-cell lymphoma [1] - The non-covalent LYN/BTK dual-target inhibitor, birelentinib (DZD8586), has presented the latest clinical data for the treatment of B-cell lymphoma [1]

Core Insights - The company, Dizhi Pharmaceutical, announced the latest research results of its two globally innovative drugs at the 67th American Society of Hematology (ASH) conference, highlighting advancements in T-cell lymphoma and B-cell lymphoma treatments [1] Group 1: Drug Development - The high-selective JAK1 inhibitor, Golixtin (generic name: Golixtin capsules), has made significant progress in the T-cell lymphoma field [1] - The non-covalent LYN/BTK dual-target inhibitor, birelentinib (DZD8586), has shown promising clinical data in the treatment of B-cell lymphoma [1] Group 2: Clinical Trial Results - In the Phase III recommended dose (RP3D) of 50mg, the overall response rate (ORR) was 84.2% [1] - Tumor remission was observed in patients previously treated with BTK inhibitors, Bcl-2 inhibitors, or BTK degraders, including those with classic BTK resistance mutations (C481X) or other BTK mutations [1] - The anti-tumor efficacy was durable, and safety was good, with no new safety issues reported during the follow-up period [1]

截至2025年12月9日 09点54分，上证科创板100指数上涨0.01%，成分股华丰科技上涨3.46%，迪哲 医药上涨3.02%，成都华微上涨2.89%，凌云光上涨2.40%，南网科技上涨2.38%。科创100ETF华夏 （588800）多空胶着，最新报价1.3元。 截至2025年12月9日 09点57分，上证科创板半导体材料设备主题指数下跌0.50%。成分股方面涨跌 互现，新益昌领涨4.42%，艾森股份上涨2.54%，天岳先进上涨2.32%；中科飞测领跌3.64%，拓荆科技 下跌1.71%，京仪装备下跌1.56%。科创半导体ETF（588170）下跌0.42%，最新报价1.42元。 民生证券指出，本季度英伟达在需求端的依然维持高景气度，包括北美大型云服务商在内的主要客 户均已进一步上调资本开支。随着产能逐季释放，Blackwell出货量有望加速提升，并成为未来几个季 度的核心增长引擎。叠加英伟达CEO强调公司对2025-2026年累计实现5000亿美元的数据中心收入具有 可见度，均指向英伟达在AI基础设施周期中的景气度仍处于高位。 消息面上，据报道，美国总统当地时间12月8日在社交媒体上发文宣布，美国政府 ...

12月9日早盘，A股、港股创新药概念均表现活跃。热门ETF中，创新药ETF（159992）截至9:57涨约 1%，成交额超1.5亿元。 成分股来看，迪哲医药、恒瑞医药、泰格医药等涨幅居前；通化金马、人福医药、特宝生物等小幅领 跌。 消息面上，2025年国家医保药品目录及首版商保创新药目录在广州发布。2025年国家医保药品目录成功 新增114种药品，有50种是一类创新药，总体成功率88%，较2024年的76%明显提高。19种药品纳入首 版商保创新药目录。 每日经济新闻 中信建投认为，国家医保谈判成功率创新高，商保目录有望成为重要增量，政策鼓励创新药发展。与此 同时，中国创新药管线国际化竞争力持续提升，出海模式持续升级，新技术推动行业快速发展。看好相 关创新药及制药企业。 资料显示，创新药ETF（159992，场外联接A类：012781；C类：012782）紧密跟踪中证创新药产业指 数，选取不超过50只最具代表性上市公司证券作为指数样本，以反映创新药产业上市公司证券的整体表 现。 ...

进一步统计，近3个月内该股累计发生3笔大宗交易，合计成交金额为2658.21万元。 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 30.57 | 1778.58 | 58.19 | -7.84 | 国投证券股份有限公司武 | 国投证券股份有限公司武 | | | | | | 汉青年路证券营业部 | 汉青年路证券营业部 | （文章来源：证券时报网） 证券时报·数据宝统计显示，迪哲医药-U今日收盘价为63.14元，上涨3.56%，日换手率为0.62%，成交额 为1.78亿元，全天主力资金净流出440.31万元，近5日该股累计下跌3.03%，近5日资金合计净流出827.41 万元。 两融数据显示，该股最新融资余额为1.91亿元，近5日增加2532.91万元，增幅为15.25%。（数据宝） 12月4日迪哲医药-U大宗交易一览 迪哲医药-U12月4日大宗交易平台出现一笔成交，成交量30.57万股 ...

| of the Call "a voltar children it form I hand" | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | 卖出营业部 | 是否为专场 | | 025-12-04 | 迪普医药 | 688192 | 58.19 1778.58 | 30.57 | 容易度多能商家感 | 型用甚至修成员感 | KO | 12月4日，迪哲医药大宗交易成交30.57万股，成交额1778.58万元，占当日总成交额的9.1%，成交价 58.19元，较市场收盘价63.14元折价7.84%。 ...

Core Insights - The pharmaceutical sector is experiencing a rise, with the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index increasing by 1.03% as of December 4, 2025, with notable gains from companies like Zai Lab (up 4.47%) and Rongchang Bio (up 4.14%) [1] Industry Overview - The pharmaceutical industry has undergone eleven rounds of national drug centralized procurement and multiple rounds of medical insurance negotiations, leading to an inevitable decline in the generic drug sector, which impacts the overall pharmaceutical industry [1] - From January to September 2025, the pharmaceutical manufacturing industry's revenue remained relatively stable, but the outlook for generic drugs is bleak, indicating a need for innovative drugs to drive future growth [1] Investment Perspective - According to Everbright Securities, future investments in the pharmaceutical sector should focus on the clinical value of drugs, addressing clinical needs of patients, as both domestic medical insurance policies and global expansion strategies increasingly emphasize clinical value [1] - The innovative drug industry chain and innovative medical devices are viewed positively based on the clinical value framework [1] Market Data - As of November 28, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index include companies like United Imaging Healthcare and BeiGene, collectively accounting for 49.75% of the index [1]

Core Viewpoint - Fosun Pharma announced that its subsidiary received approval from the National Medical Products Administration for clinical trials of the innovative oral small molecule drug FXS887 for advanced malignant solid tumors, with no approved therapies targeting the same pathway expected until December 3, 2025 [2] Group 1: Company Developments - Fosun Pharma's FXS887 is aimed at treating advanced malignant solid tumors and is notable for being the first of its kind in its target pathway [2] - The approval for clinical trials marks a significant step in the development of innovative therapies within the company [2] Group 2: Market Activity - The pharmaceutical and biotechnology sector saw increased activity, with the STAR Market pharmaceutical ETF (588130) rising by 0.99%, and several holdings such as Yirui Technology, Zai Lab, Rongchang Bio, Dize Pharmaceutical, and Yifang Bio each increasing by over 3% [2] Group 3: Industry Insights - Everbright Securities suggests that investment in the pharmaceutical sector should increasingly focus on the clinical value of drugs, addressing the needs of patients and healthcare providers [2] - The report emphasizes that both domestic healthcare policies and global expansion strategies are placing higher premiums on clinical value, indicating a positive outlook for the innovative drug and medical device industries [2]

Core Insights - The A-share private placement market is experiencing significant participation from public funds in 2025, with 33 fund companies involved and a total allocation amounting to 17.3 billion yuan, representing a 140% increase compared to the entire year of 2024 [1][5][8] Group 1: Market Participation - Public funds have shown a marked increase in enthusiasm for private placements, with a total allocation of 17.3 billion yuan in 2025, up from 7.2 billion yuan in 2024, indicating a growth of over 100 billion yuan [5][6] - Leading public fund companies include E Fund with 3.687 billion yuan, followed by GF Fund, Fortune Fund, and China Universal Fund with allocations of 2.288 billion yuan, 1.529 billion yuan, and 1.463 billion yuan respectively [5][6] Group 2: Investment Focus - The investment focus of public funds is heavily concentrated in hard technology sectors, particularly in semiconductors, artificial intelligence, and innovative pharmaceuticals, reflecting a strong alignment with the ongoing "technology bull" market [6][8] - Notable allocations in the electronics sector reached 7.45 billion yuan, while the biopharmaceutical sector saw allocations of 5.6 billion yuan, targeting companies like Cambricon, Chipone, and innovative drug firms [6][8] Group 3: Market Drivers - The resurgence of private placements is driven by three main factors: policy incentives, a safety margin due to discount pricing, and significant profit potential observed by participating public funds [8] - The current trend shows increased participation, improved returns, and a strong focus on technology and high-end manufacturing sectors, with expectations for continued growth in public fund involvement in private placements [8]